FDA grants priority review to Pfizer/BioNTech Covid-19 vaccine; decision on approval expected by January 2022

Pfizer and BioNTech said Friday that the US Food and Drug Administration has granted priority review designation to their application for full approval of their Covid-19 vaccine, and an FDA official said the decision will come 'soon'. The FDA official told CNN on Friday that a decision on full approval is likely to come within two months. The agency considers this matter a priority, said the official, who asked not to be named because they were not authorized to speak publicly on the matter.